Pre‐clinical validation of a selective anti‐cancer stem cell therapy for Numb‐deficient human breast cancers

Abstract The cell fate determinant Numb is frequently downregulated in human breast cancers (BCs), resulting in p53 inactivation and an aggressive disease course. In the mouse mammary gland, Numb/p53 downregulation leads to aberrant tissue morphogenesis, expansion of the stem cell compartment, and e...

詳細記述

書誌詳細

出版年:	EMBO Molecular Medicine
主要な著者:	Daniela Tosoni, Sarah Pambianco, Blanche Ekalle Soppo, Silvia Zecchini, Giovanni Bertalot, Giancarlo Pruneri, Giuseppe Viale, Pier Paolo Di Fiore, Salvatore Pece
フォーマット:	論文
言語:	英語
出版事項:	Springer Nature 2017-03-01
主題:	breast cancer cancer stem cells Numb p53 primary‐derived xenografts
オンライン･アクセス:	https://doi.org/10.15252/emmm.201606940